Corporate - Media & Press - Press Release - Biacore
SpotBot Microarrayer now has Biacore Flexchip SPR Application Support.
Sunnyvale, CA, Tuesday, June 20, 2006– TeleChem announced today the widely used SpotBot Microarrayer now has specific application support for the Biacore Flexchip SPR analysis system. Biacore, which was recently acquired by GE Healthcare, is the current market leader in SPR (surface plasmon resonance) detection platforms. The combination of the SpotBot, 946 Micro Spotting Device, and Flexchip system empowers users to profile hundreds of proteins simultaneously in real time. To see screen shots of the application software click here. Applications include: kinetic profiling to select for further characterization, mapping binding domains and epitopes, assessing the binding contributions of post-translational modifications such as phosphorylation, methylation or acetylation, and ranking antibody candidates for early selection. The details of the software upgrade were worked out with experienced Biacore application specialists Michael Murphy and Brian Lang. The programs are now available for download to all SpotBot users at http://www.myspotbot.com.
TeleChem International is a privately owned high-tech company located in the heart of California’s Silicon Valley. Our products and services are provided by three corporate divisions: ArrayIt® Life Sciences Division, Chemicals Division, and a Diagnostics Division. The ArrayIt® Life Sciences Division offers a complete microarray technology platform that empowers >10,000 laboratories to use microarrays for human genome exploration, basic research, drug discovery, and myriad life sciences applications. Nearly every major research institution uses our patented microarray manufacturing technology (U.S. 6,101,946) and supporting products and services. The Chemicals Division provides import and export services and government contract manufacturing in the area of industrial chemicals for plastics, fire control, water treatment, agriculture, industrial and institutional compounding, and green energy. The Diagnostics Division holds key patents in the United States (6,913,879), Singapore (94899), New Zealand (523560), and other countries for its revolutionary “multi-patient” genotyping technology, which allows as many as 100,000 patients to be tested on a single microarray. Arrayit Diagnostics enables genotyping and disease diagnostics by providing testing kits, services, and technology transfer opportunities for disease screening and testing organizations.
Copyright 1993-2018 Arrayit Corporation. All rights reserved.